Article

New drug application accepted for bepotastine

ISTA Pharmaceuticals' new drug application for bepotastine ophthalmic solution (Bepreve) has been accepted for review by the FDA, the company announced in a prepared statement.

Irvine, CA

-ISTA Pharmaceuticals’ new drug application for bepotastine ophthalmic solution (Bepreve) has been accepted for review by the FDA, the company announced in a prepared statement. The company is seeking approval for the solution to be used as an eye drop treatment for ocular itching associated with allergic conjunctivitis.

Phase III clinical studies conducted with the solution showed highly statistically significant reductions in the primary endpoints of ocular itching. The results also showed that it had a statistically significant effect on the rapidity of response and the additional signs or symptoms of ocular allergy, including improvement in nasal symptoms. No serious ocular adverse events were reported in patients who received the drops.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.